SynthesisFrontiers in pharmacology2025
The potential value of quercetin for colorectal cancer: a systematic review and a meta-analysis of preclinical studies.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Quercetin as a Multifunctional Flavonol: Molecular Insights and Therapeutic Applications.Molecules (Basel, Switzerland) · 2026Review
- Enhancing Targeted Colorectal Cancer Therapies with Natural Products: Mechanistic Pathways.Biomedicines · 2026Review
- Mechanism of action of alkaloids inOncology letters · 2026Article
- Quercetin Affects Carcinogenic Phenotype of Breast and Lung Cancer Cells Differentially Through Sterol Regulation Mediated by MALAT1 Perturbation.Chemistry, an Asian journal · 2026Article
- Anti-Cancer Effects of Quercetin: What Role Does the Gut Microbiota Play?Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Quercetin, a ubiquitous natural flavonoid present in numerous medicinal plants and foods, has been widely recognized for its various bioactive properties. However, despite its potential, the preclinical animal studies evaluating its therapeutic efficacy in colorectal cancer (CRC) remain inadequate, and the existing clinical research in this area is still limited in quantity. These deficiencies hinder the practical application of quercetin in the treatment of colorectal cancer. Methods: Our comprehensive review involved systematically searching major databases-including PubMed, Web of Science, and Embase-up to April 2025 for relevant preclinical studies. The SYRCLE risk of bias tool was employed by researchers to evaluate each entry. Subsequently, data analysis was conducted using the statistical software Review Manager 5.4. Results: The results of our meta-analysis showed that quercetin treatment not only significantly reduced the incidence of CRC (SMD-1.22, 95% CI: -0.26 to -0.38, p = 0.004), but also alleviated inflammation and oxidative stress compared with the control group. Quercetin treatment effectively improved the degree of crypt lesions (SMD-1.40, 95%CI: -2.53 to -0.26, p = 0.02) and alleviated precancerous lesions in the animal model of CRC. In terms of tumor cell proliferation, quercetin had a significant inhibitory effect on cell proliferation during treatment, as determined by PCNA analysis (SMD -8.22, 95% CI: -10.48 to -5.95, p < 0.00001). Quercetin may promote apoptosis during treatment, but this hypothesis has not been supported. Conclusion: Our study indicates that quercetin exerts beneficial effects across multiple facets of CRC treatment. Nonetheless, precise evaluation of quercetin's impact on colorectal cancer demands further high-quality, large-scale animal and human studies to confirm our findings. Systematic Review Registration: https://inplasy.com, identifier INPLASY202550014.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.